Kornimate/medical-research-clean huggingface dataset:
network pharmacology prediction: mechanism study of puerarin in the treatment of giant cell tumors of bone

Conditions: Giant Cell Tumors

Summary: based on network pharmacology analysis, this study aims to explore the potential therapeutic targets and molecular mechanisms of puerarin on giant cell tumor of bone (gctb) genes.

the giant cell tumor of bone's pathological genes were discovered from disgenet and genecards databases. the therapeutic genes of puerarin were gathered from swiss target prediction, ctd(comparative toxicogenomics database), pharmmapper, and tcmsp databases (traditional chinese medicine systems pharmacology database and analysis platform). cytoscape software was used with the mcode algorithm to calculate key potential therapeutic targets of puerarin against gctb. the bulk rna-seq datasets (gse102193) were used to identify differential expression of potential therapeutic genes. the sc rna-seq (gse168664) was utilized to determine the expression distribution of different cell clusters. essential targets of puerarin against gctb underwent function and pathway enrichment assays to elucidate biological processes and signaling pathways. furthermore, the investigators conducted a comparison to determine if the primary biological processes and pathways following denosumab treatment exhibit resemblances to the potential mechanisms of puerarin action. molecular docking and dynamics simulation were conducted to evaluate interactions between selected potential therapeutic targets and puerarin. immunohistochemical (ihc) and immunofluorescence (if) staining were performed to identify the expression of crucial markers in human gctb tissue. expression levels of pivotal genes in primary bmsc cells and primary gctb cells and their alteration following puerarin treatment in primary gctb cells were evaluated.the significance of differences between groups was estimated by the student t-test or wilcoxon test. in all the statistical analyses, data with two-tailed p \< 0.05 were considered statistically significant.

Eligibility criteria:
inclusion criteria: 1. diagnosed as a patient with giant cell tumor of bone; 2. performing surgical treatment in 1st hospital of sysu; 3. having complete clinical registration information; 4. preserve surgical or puncture specimens; exclusion criteria: 1. non bone giant cell tumor patients; 2. no surgical treatment was performed; 3. incomplete clinical information registration; 4. no preserved surgical or puncture specimens.

Keywords: giant cell tumors puerarin treatment traditional chinese medicine network pharmacology
a comparison between home-made vitrification & thawing media and a commercially available brand on blastocyst

Conditions: Blastocyst Disintegration

Summary: this study was conducted to evaluate and compare cryo-survival, re-expansion, and implantation rates of day 5/6 human blastocysts that were vitrified with home-made media (hm) according to (shady grove protocol) and warmed with gradual thawing hm according to (kuwayama protocol)with global fast freeze/thaw kits (lifeglobal, canada).

group 1 blastocysts were vitrified with the vit hm according to shady grove protocol using open system on cryotopvit. device and thawed with gradual thawing technique using hm according to kuwayama protocol. group 2 blastocysts were cryopreserved with the global fast freeze kitusing open system on cryotopvit. device and thawed using gobal fast thaw kit. blastocysts were subsequently cultured for 6-8 h, assessed for survival and expansion, then transferred and the percentages of positive hcg, clinical pregnancy, implantation, multiple pregnancy and abortion were recorded.

Eligibility criteria:
inclusion criteria: * age of the patients 22-37 * all vitrified \& thawed blastocyst. * unexplained cases or ovarian factors for infertility. exclusion criteria: * extremes of age * cases of uterine factor * endometriosis

Keywords: vitrification blastocysts home-made media
non-surgical treatment approaches in patients with newly diagnosed lateral epicondylitis: a randomized clinical trial

Conditions: Tennis Elbow

Summary: lateral epicondylitis (tennis elbow) is a painful musculoskeletal condition, which is considered to be due to overuse, over-stress or over-exertion of the wrist extensors of the forearm, especially extensor carpi radialis brevi. the aim of this study is to the compare the short-term effects of different physiotherapy approaches on pain, function and grip strength in the rehabilitation of patients with lateral epicondylitis.

lateral epicondylitis (tennis elbow) is a painful musculoskeletal condition, which is considered to be due to overuse, over-stress or over-exertion of the wrist extensors of the forearm, especially extensor carpi radialis brevi. different treatment approaches are described in the literature. the primary aim of the treatment approaches are decrease the pain and improve the functional level in patients with lateral epicondylitis. thus, decreasing pain and regaining the functional performance in the daily living activity is essential in early diagnosed patients. the aim of this study is to compare the short-term effects of different treatment approaches on pain, function and grip strength in the rehabilitation of patients with lateral epicondylitis.

Eligibility criteria:
inclusion criteria: * diagnosed with tennis elbow, * and the duration of symptoms was between 8 and 10 weeks, * and pain over the lateral epicondyle, pain during grip strength testing, and pain with one of the following tests: extensor carpi radialis test (i.e., resisted middle-finger extension), resisted wrist extension, or passive stretch of the wrist extensors. * furthermore, the participants had to agree to abstain from any other form of treatment during their involvement in this study exclusion criteria: * patients with inflammatory, autoimmune, endocrine or kidney diseases, cubital tunnel syndrome, carpal tunnel syndrome, radiculopathies due to cervical disc pathologies, additional shoulder-hand-wrist pathologies, inflammatory arthritis, upper extremity operations or traumas, * allergies to adhesive tape, * and the patients who received corticosteroid injection due to lateral epicondylitis within the last 3 months

Keywords: tennis elbow pain shock wave kinesio taping
study to determine the efficacy, safety, tolerability & pharmacokinetics of ro 205-2349 in patients with type 2 diabetes mellitus

Conditions: Diabetes

Summary: the objective of the study is to determine the dose(s) of ro 205-2349 which, when compared to placebo, are efficacious, safe and tolerable in improving glycemic control in patients with type 2 diabetes. doses of 2 to 5 mg/day will be studied.


Eligibility criteria:
inclusion criteria: * age 35 to 75 * type 2 diabetes for longer than 3 months * hba1c (glycosylated hemoglobin a1c) greater than 7.0% at screening * fpg (fasting plasma glucose) greater than 126 mg/dl at screening * bmi (body mass index) less than 40 kg/square meter exclusion criteria: * type i diabetes * type 2 diabetes patients currently treated with insulin * type 2 diabetes patients currently or previously treated with actos, avandia or rezulin * fpg (fasting plasma glucose) greater than 270 mg/dl at baseline * impaired liver or kidney function * triglycerides greater than 600 mg/dl * uncontrolled hypertension * pregnant or lactating women * women not using adequate contraception
efficacy of colchicine in improving clinical outcomes in patients with mild to moderate covid-19 pneumonia in lahore: a randomized control trial

Conditions: COVID - 19

Summary: this study is for patients suffering from covid-19 pneumonia (mild to moderate cases) ; especially in developing countries where expensive drugs are not available. colchicine is an economically favourable anti inflammatory drug readily used for gout patients but is being given experimentally in covid 19 patients . study has been designed in this way that drug has been given carefully to patients on which there will be no to minimum side effects . it is only to see beneficial effects if any present in covid pneumonia patients which will be observed by clinical \& lab improvement.

colchicine, an anti-inflammatory drug used conventionally to treat gout and pericarditis. this study shows effectiveness of colchicine in enhancing clinical outcomes in mildly to moderately severe covid-19 pneumonia patients. improvement will be observed in terms of shorter hospital admissions and oxygen dependency .

Eligibility criteria:
inclusion criteria: * patients with laboratory-confirmed covid-19 infection through a pcr test using a nasopharyngeal swab specimen, or the presence of at least two of the following four inflammatory criteria: c-reactive protein (crp) level \> 4 mg/dl, d-dimer level \> 1 mg/l, ferritin level \> 1000 ng/ml, along with fever ≥ 38 °c and respiratory distress patients having supplemental oxygen requirement. patients who provide informed consent to participate in the study. patients having normal levels of serum ca2+ and k+; qt interval \<450 ms at 12 derivations ecg (colchicine has been associated with potential cardiac side effects, including disturbances in electrolyte levels and qt interval prolongation. normal levels of these electrolytes help minimise the risk of cardiac arrhythmias or other adverse events. exclusion criteria: known hypersensitivity or allergy to colchicine or any of its excipients. patients with an estimated glomerular filtration rate (egfr) below 45 ml/min/1.73 m\^2 or advanced liver disease (child-pugh class b or c). patients taking medications known to have significant interactions with colchicine, such as strong cyp3a4 inhibitors (e.g., clarithromycin, ketoconazole), p-glycoprotein inhibitors (e.g., cyclosporine), or medications associated with myelosuppression (e.g., azathioprine, cyclophosphamide). patients with pre-existing medical conditions that, in the opinion of the investigator, could pose a significant risk or interfere with the interpretation of the study results (e.g., severe heart failure, uncontrolled arrhythmias, uncontrolled diabetes, or active malignancies). pregnant or lactating individuals. patients deemed by the investigator to be in imminent danger of death or unlikely to survive the duration of study due to some other disease
treatment of claudication with a peristaltic pulse pneumatic device

Conditions: Intermittent Claudication

Summary: the purpose of this study is to evaluate the efficacy of a non-invasive peristaltic pulse pneumatic device (pcd) in the treatment of intermittent claudication in patients having documented peripheral arterial disease (pad). the pneumatic device to be studied is fda approved for the treatment of venous disease. while anecdotal evidence exists supporting a decrease in claudication symptoms, there are no previously published data on studies employing this compression device in the treatment of arterial disease. the investigators' primary hypothesis is that patients randomized to the intervention arm of the trial will experience an increase in mean walking ability as compared to the group receiving medical standard of care.

peripheral arterial disease (pad) is a common disorder, affecting 12% of adults older than 50 years of age. approximately one third of these patients experience intermittent claudication, defined as pain in the thigh or calf muscles during walking and that resolves with rest. lower extremity pain is often severe enough to significantly limit ambulation, forcing many patients to seek medical care. current treatments include two fda-approved medications, supervised walking programs, arterial angioplasty and/or stent placement, and open arterial bypass surgery. the problem is that noninvasive treatments are oftentimes ineffective, while invasive treatments are effective but expensive. a non-invasive lower extremity treatment that has shown success in treating lymphedema and venous insufficiency will be studied during this protocol to assess its effects on claudication symptoms. half of the participants in this prospective, single-center randomized controlled trial will be treated with a pneumatic compression device in a home treatment program, while half will receive standard medical therapy. if effective, potential benefits are high, providing relief of personal disability and avoidance of costly surgical intervention.

Eligibility criteria:
inclusion criteria: * consistent claudication symptoms for at least 6 months * abis at rest as follows: 0.5\>abi\<0.8 minimally on one leg exclusion criteria: * refuses to consent * unlikely to be compliant with protocol * unable to perform treadmill test * current use of cilostazol (pletal) or pentoxyphylline (trental) * lower extremity surgery or endovascular procedure within the last 3 months * currently has a non-healing wound on either leg * dvt in the past 3 months * unstable hypertension, angina, uncontrolled glucose levels * participating in a supervised exercise regimen * claudication medications regime changed within the last 3 months * diagnosis of raynaud's disease * requires a custom fabricated boot appliance * single limb amputees meeting inclusion criteria may participate in this study

Keywords: claudication pneumatic compression device
evaluation of earlysense home care tele-monitoring device

Conditions: Myocardial Infarction; Cardiac Surgery

Summary: the aims of the present study are to evaluate the information obtained by the earlysenese monitoring system and examine correlation of the obtained data and clinical events.

the earlysense home care system developed by earlysense, ltd., is a contact-less tele-monitoring system. the system is intended for continuous monitoring of patients' respiration rate, heart rate and patient's motion. the system, which monitors the patient while in bed, consists of a piezoelectric sensor that produces an electrical signal in response to physiological stimulation, and a microprocessor control unit that analyzes the recorded signal and identifies respiratory and heart rates and patient motion, while patient is in bed,. in addition, the system indicates patient's in or out of bed status. the system also provides alerts if either of the physiological parameters cross predefined threshold settings (e.g., high/ low heart rate or respiratory rate, or motion or time in bed). the system saves patient's parameters and then flags the patients, as those to have changes in their vital signs and motion, or those that do not have noteworthy changes during recent hours of monitoring. flagging of the patients are based on changes detected in patients' baseline vital signs (heart and respiratory rates and patterns) and well as recognition of changes in patients motion and in and out of bed status in comparison to set thresholds. the aim of this study is to evaluate relevance of the information (vital sign trends, alerts and flags) as provided by the earlysense home care tele-monitoring system to medical staff in sheba medical center's heart rehabilitation institute (shelev) in order proactively monitor patients at home. the correlation between the earlysense system alerts and flags to patient deterioration and hospital readmission will be studied.

Eligibility criteria:
inclusion criteria: 1. patients who resided in shelev following a cardiac event (cardiac surgery, myocardial infarction, pacemaker implantation or other cardiac interventions ) 2. age ≥ 21 years 3. any patient hosted in shelev with geographically resident within 50 km from sheba medical center 4. patients agrees to sign the consent form and able to comply with study protocol. 5. sleeps on a mattress exclusion criteria: 1. planned readmission within 30 days of discharge from hospital 2. discharge to hospice care. 3. patients with cognitive disabilities 4. patient's major treating hospital is not the sheba medical center

Keywords: telemonitoring
the effect of steep trendelenburg position on neurocognitive functions in robotic radical prostatectomy cases

Conditions: Neurocognitive Disorder; Robotic Assisted Laparoscopic Radical Prostatectomy; Near Infrared Spectroscopy

Summary: the aim of this study is to evaluate the effects of the steep trendelenburg position in robotic prostatectomy cases, where anesthesia depth is monitored using bis and cerebral perfusion is tracked with nirs, and to determine the incidence of neurocognitive dysfunction using the moca test in the postoperative period. steep trendelenburg position and co₂ pneumoperitoneum during robotic radical prostatectomy lead to significant changes in intracranial pressure and cerebral oxygenation, which may contribute to postoperative neurocognitive dysfunction (pocd). monitoring anesthesia depth with bispectral index (bis) and cerebral perfusion with near-infrared spectroscopy (nirs) may help detect early neurocognitive changes, and moca test assessments will reveal a measurable decline in cognitive function postoperatively.


Eligibility criteria:
inclusion criteria: * age ≥ 65 years * asa ii-iii risk score * patients scheduled for robotic radical prostatectomy * patients who voluntarily agree to participate exclusion criteria: * age \< 65 years * history of neurological or psychiatric disorders * inability to undergo robotic surgery * conversion to open prostatectomy during surgery * patients who do not consent to participate
the registry of genetic expression of taiwan urologic cancer

Conditions: Urologic Cancer

Summary: this project is a nationwide precision medicine program for urothelial carcinoma and renal cell carcinoma.

this project providing free and immediate next-generation gene sequencing testing for patients with urothelial and renal cell carcinomas that have is diagnosed or that have previously received systemic therapy. the goal of this project is to assist participating institutions in integrating next-generation sequencing results and building a real-time data storage and sharing platform, as well as establishing a tumor molecular biological atlas of taiwanese patients with urothelial carcinoma and renal cell carcinoma. the data will be linked with clinical prognosis to facilitate the rapid screening of patients for effective potential therapeutic drugs and clinical trials, which is anticipated to prolong the survival rate of patients.

Eligibility criteria:
inclusion criteria: 1. ages 20 and above. (age \>= 18 years old from january 1, 2023). 2. pathological reports showed renal cell carinoma or urothelial carcinoma. 3. muscle-invasive bladder cancer or positive of n/m grade, utuc of t2 at least or positive of n/m grade, or stage iii/iv rcc 4. willingness to provide the residual biopsy/operative tumor samples for study. 5. life expectancy more than 3 months. 6. patients fully understand the protocol with the willingness to have regular follow-up. exclusion criteria: 1. inability to cooperate by providing a complete medical history. 2. ineligible tumor tissue samples for next-generation sequencing of genetic testing. 3. undesirable compliance. 4. having a known additional malignancy that is progressing or has required active treatment within the past 3 years. participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervical carcinoma in situ) that have undergone potentially curative therapy are not excluded.
comparison of cranioplasty with peek and titanium

Conditions: Brain Injuries; Hematoma of Head; Skull Defect

Summary: decompressive craniectomy is suggested as an effective surgical intervention for patients with high intracranial pressure. recently, various customized artificial materials are increasingly employed, e.g., titanium and polyetheretherketone (peek). the application of peek in cranioplasty is increasing, while its comprehensive evaluation in clinical practice is still insufficient, especially when comparing with the effects of titanium implant. we thus designed the study to evaluate the comprehensive effects of the cranioplasty with peek vs titanium.

decompressive craniectomy (dc) is suggested as an effective surgical intervention for patients with high intracranial pressure. for the skull defect after dc, cranioplasty could pro-vide protection, aesthetic and even functional improvements. the autologous bone flap (abf) was once thought to be an optimal autograft for repairing \[8\]. while accumulated studies reported abf related disadvantages. recently, various customized artificial materials are increasingly employed, e.g., titanium and polyetheretherketone (peek). titanium is a widely applied metal material for cranioplasty, attribute to its high strength, bio-compatibility and comparatively low material cost. currently, pre-operative three dimensional (3d) reconstruction of titanium brings a customized implant for optimal shaping effect. however, titanium implant is still confronted with complications of infection, implant exposure, etc. peek is a novel polymer used to rebuild the personalized construction. through the precise computational reconstruction of high-resolution computed tomography (ct) scanning, the customized peek could more accurately rebuild the complex cranial and maxillofacial structure. the application of this material in cranioplasty is increasing, while its comprehensive evaluation in clinical practice is still insufficient, especially when comparing with the effects of titanium implant. we thus designed the study to evaluate the comprehensive effects of the cranioplasty with peek vs titanium. the data of the patients implanted peek or titanium in four years in our institute were retrospectively collected and evaluated, in respects of the general information of patients, postoperative complications, shaping effects, and psychosocial improvements, to display a comprehensive evaluation for these two implants.

Eligibility criteria:
inclusion criteria: * patients underwent cranioplasty with peek or titanium. * patients underwent cranioplasty and had complete data and 6-month follow-up records. exclusion criteria: * patients underwent cranioplasty with other material or abf. * patients had incomplete data or follow-up records.

Keywords: cranioplasty peek titanium outcomes complications subcutaneous effusion
a prospective multicenter registry of patients with sleep disordered breathing treated with dreamstation bipap autosv.

Conditions: Central Sleep Apnea; Mixed Sleep Apnea; Cheyne-Stokes Respiration; Complex Sleep Apnea

Summary: this multi-center observational study will prospectively collect data from patients who have an indication for servo ventilation therapy. this registry is intended to characterize the patient populations that may benefit from dreamstation bipap autosv therapy (pr ds-autosv, philips respironics, monroeville, pa) in real life settings. in addition, this registry will assess adherence to the pr ds-autosv therapy, the therapeutic benefits, collect morbidity and mortality data of servo ventilation in patients with central sleep apnea (csa) and complex sleep-disordered breathing (sdb).


Eligibility criteria:
inclusion criteria: * indication and prescription of pr ds-autosv * polysomnographic (psg) or polygraphic (pg) documentation of sleep-disordered breathing requiring servo ventilation exclusion criteria: * patients with hfref - heart failure and low ejection fraction (ef ≤ 45%) and predominant csa (\> 50 % of events) * patients not able to receive positive airway pressure support through a mask due to surgical procedure or anatomical condition * chronic conditions with life expectancy \< 1 year * significant chronic obstructive pulmonary disease (copd) with an fev1/vc \< 70% (gold iii) * respiratory insufficiency requiring long-term oxygen therapy * daytime hypercapnia at rest (pco2 \> 45 mmhg) * cardiac surgery, pci, myocardial infarction, unstable angina, within 12 weeks prior to enrolment * cardiac resynchronization or pacemaker implantation within the last 6 months * untreated or therapy refractory restless legs-syndrome (rls)